$3.94
0.76%
Nasdaq, Sep 18, 04:00 pm EDT. Closed.
ISIN
US04301G2012
Symbol
ARTL

Artelo Biosciences Inc Stock price

$3.94
-2.63 40.02% 1M
-61.85 94.01% 6M
-29.00 88.04% YTD
-146.18 97.38% 1Y
-235.82 98.36% 3Y
-2,012.96 99.80% 5Y
-4.06 50.75% 10Y
-4.06 50.75% 20Y
Nasdaq, Closing price Fri, Sep 18 2026
-0.03 0.76%
ISIN
US04301G2012
Symbol
ARTL
Industry

Is Artelo Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$2.2m
Enterprise Value
$-2.0m
Net debt
positive
Cash
$4.2m
Shares outstanding
4.2m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
0.4
Financial Health
Equity Ratio
-45.4%
Return on Equity
1,012.5%
ROCE
-221.4%
ROIC
-1,302.2%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
-
EBIT
$-11.1m
Net Income
$-12.7m
Free Cash Flow
$-12.6m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-5.1%
Net Income
-20.7%
Free Cash Flow
-131.7%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-4.7
FCF per Share
$-3.0
Short interest
6.6%
Employees
7
Rev per Employee
$0.0

Artelo Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Artelo Biosciences Inc forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Artelo Biosciences Inc forecast:

Hold
50%
Sell
50%

Financial data from Artelo Biosciences Inc

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.25 7.25
62% 62%
-
- Research and Development Expense 3.82 3.82
37% 37%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -11 -11
5% 5%
-
Net Profit -13 -13
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about Artelo Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Artelo Biosciences Inc Stock News

Neutral
GlobeNewsWire
3 days ago
Once-daily, oral ART27.13 reduced body weight by approximately 20% in obese mice, matching the weight loss achieved with semaglutide, the active ingredient in Ozempic ® and Wegovy ®
Neutral
GlobeNewsWire
23 days ago
Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026 Shares Expected to Begin Trading on a Split-Adjusted Basis on August 31, 2026
Neutral
GlobeNewsWire
about one month ago
SOLANA BEACH, Calif., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc.  (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signalling pathways to develop treatments for people living with cancer, pain, dermatologic, or neurological conditions, today announced that the Japanese Patent Office has issued a notification of allow...
More Artelo Biosciences Inc News

Company Profile

Artelo Biosciences, Inc. is a development stage company, which engages in discovering, licensing, developing and commercializing treatments that modulate the endocannabinoid system. The company was founded by James Manley on May 2, 2011 and is headquartered in San Diego, CA.

Head office United States
CEO Mr. Gorgas
Employees 7
Founded 2011
Website artelobio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today